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ABSTRACT 
A combination of bupropion hydrochloride and thiothixene was 
compared with a combination of placebo and thiothixene in a double blind 
investigation in thirty-eight patients meeting the DSM-III criteria for 
schizophrenia and also for atypical depression. These patients had to 
demonstrate a Hamilton Depression Scale score of at least eighteen prior 
to study entry. Assessments for efficacy and safety were performed at 
baseline and at regular intervals throughout the study. Patients were 
given physical exams with complete clinical laboratory workups prior to 
and after the study active treatment phase to document the safety of the 
respective treatments. 
Of the nineteen subjects originally included in each treatment 
group, eighteen completed four full weeks of study treatment. Patients 
in both treatment groups were not significantly different at baseline on 
all measures. A significantly greater number of subjects (9) dropped out 
from the bupropion and thiothixene group than from the placebo and 
thiothixene group (2) prior to reaching the full ten week period. The 
patients who dropped out were significantly more psychiatrically ill 
than those who remained as measured by the Brief Psychiatric Rating 
Scale. 
Both groups became less depressed as measured on the Hamilton 
Depression Scale over four and ten weeks, though only when the dropouts 
were included in the analysis did the placebo and thiothixene group 
demonstrate a greater degree of improvement than the bupropion and 
thiothixene group. The overall psychiatric pathology as measured by the 
Brief Psychiatric Rating Scale was decreased to a significantly greater 
degree by the placebo and thiothixene control group than by the 
bupropion and thiothixene group at four weeks but not at ten weeks. 
Global ratings of patients overall psychiatric status also showed 
improvement over time. 
Treatment group effects on separate psychiatric syndromes as 
measured by the Brief Psychiatric Rating Scale factor scores were 
divergent. Significant decreases on the thought disorder and the 
anergia factor scores from baseline were observed for both treatment 
groups to a similar degree. However, patients in the thiothixene and 
placebo group demonstrated greater improvement over time than the 
bupropion and thiothixene group on the anxiety and depression factor 
score. Neither group showed improvement from baseline on the activation 
factor scores nor the hostilty and depression factor scores. 
Neurological side effects were not significantly different between 
groups. No differences between group were observed on the physical and 
clinical chemistry examinations of patient health nor on 
electrocardiogram or electroencephalogram. The Treatment Emergent 
Symptom Scale showed statistically significant between group 
differences. The bupropion and thiothixene group reported twice the 
incidence of dry mouth and constipation than the placebo and thiothixene 
group, while the latter group reported increase in appetite, more 
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1. 
INTRODUCTION 
The treatment of depressive syndromes in schizophrenic patients has 
been problematic. The tricyclic antidepressants (TCA's) and monoamine 
oxidase inhibitors (MAOI's) have not been shown to be effective in 
treating depression as a secondary symptom of schizophrenia (Becker, 
1985; Siris et al., 1978), and in fact have been implicated in inducing 
psychosis in previously stabilized schizophrenic patients (Siris et al., 
1978). While some antipsychotic medications have been shown to be 
effective in treating both psychosis and depression (Becker, 1983), 
there is no established treatment for depression coexisting with 
schizophrenia if depression does not resolve as a result of treatment 
with the antipsychotic phenothiazines or butyrophenones. Furthermore, 
clinically significant symptoms of depression of ten occur in patients 
who have had their psychosis succesfully treated with antipsychotics 
(Mandel et al., 1982). Depression often is a secondary symptom in 
schizophrenia (Weisman et al., 1977; Siris et al., 1981; Carr, 1983; 
Becker,1985), and depressed schizophrenics are more likely to relapse 
following successful treatment than nondepressed schizophrenics (Mandel 
et al., 1982; Glazer et al., 1981). 
The primary focus of the present study is to attempt to 
successfully treat this resistant patient population with the novel 
antidepressant bupropion. The pharmacological profile of this 
chemically distinct antidepressant makes it unlikely that it will 
potentiate the sedative and anticholinergic properties of the 
antipsychotic drugs, thus making the use of this medication in 
combination with antipsychotics feasible. As the population we are 
dealing with must be maintained on their antipsychotic in order to 
2. 
prevent the relapse of their psychotic symptomotology , this would make 
bupropion an ideal pharmacotherapeutic agent for treating their 
depressive symptomotology without increasing the chance that adverse 
reactions will occur . 
Bupropion hydrochloride is both chemically and pharmacologically a 
novel antidepressant compound . It is structurally unrelated to the 
tricyclic antidepressants (TCA's) or monoamine oxidase inhibitors 
(MAOI ' s) and is neither sedating, anticholinergic , nor cardiotoxic 
(Dufresne et al . , 1984 ; Van Wyck Fleet et al . , 1983) . More importantly , 
bupropion appears to be effective in treating Major Depression in many 
patients who have in the past not responded to the TCA's and MAOI's 
(Stern et al . , 1983). 
While effective in treating major depression (Dufresne, et al 1984 , 
Preskorn and Othmer, 1984), it has not been established whether 
bupropion can be useful in treating depression secondary to other 
psychiatric syndromes . Bupropion was chosen for this study because it 
is chemically and pharmacologically distinct from the TCA's and the 
MAOI ' s that have been used for this purpose in the past . Unlike the 
TCA ' s it does not block the reuptake of norepinephrine (NE) or of 
5- hydroxytryptamine (5-HT) from synapses . Also , it does not have any 
effect on either type A or type B monoamine oxidase (Ferris et al ., 1981 
and 1983) . It has been demonstrated in a drug discrimination paradigm 
in the rat that bupropion ' s internal cue is not blocked by neuroleptics 
while that of the tricyclic antidepressants was so affected (Blitzer and 
Becker, 1985). This led us to hypothesize that bupropion might be 
effective in treating depression in these patients when given 
concomitantly with an antipsychotic since its mechanism of action might 
3 . 
not be interfered with in the same manner as the TCA ' s . Previous 
studies in which the tricyclic antidepressant or monoamine oxidase 
inhibitors did not decrease depressive symptoms when given concomitantly 
with antipsychotic could be the result of the blockade of the more 
typical antidepressants ' mechanism of action by the antipsychotic . The 
possibility that bupropion may work by a mechanism distinct from these 
agents makes for the chance of it being effective where these 
medications have previously failed . Clinical studies in depressive 
syndromes have demonstrated that bupropion is effective in patients 
found refractory to TCA's (Stern, 1983) . Furthermore , the fact that 
bupropion is apparently a much safer medication than the MAOI ' s or TCA's 
which are still often used in attempts to treat depressive symptoms 
secondary to schizophrenia makes this study less of a risk to the 
subjects than their usual treatment . Bupropion, unlike TCA's , is not 
likely to potentiate the anticholinergic or sedative effects of 
antipsychotics as it does not possess these properties. (Van Wyck Fleet 
et al . , 1983) . Unlike MAOI's , there is no concern about a possible 
hypertensive crisis due to unmetabolized pressor substances such as 
tyramine (Fowle et al . , 1983). 
A secondary aspect of this study concerns whether the so called 
"negative symptoms" of schizophrenia can be influenced by bupropion 
treatment. These negative symptoms of schizophrenia can be more readily 
understood as deficit symptoms; that is , they describe the absence of 
certain perceptual skills or emotive behavior that are found in 
psychiatrically healthy individuals . Examples of these symptoms include 
anhedonia, apathy, emotional blunting, social isolation, poor hygiene , 
and poverty of speech. These symptoms are often prominent in chronic 
4. 
schizophrenics and notoriously resistant to treatment (Andreasan, 1982) . 
In a study of bupropion in major depressive syndrome Dr. Robert Becker 
and myself found that patients became more active and interested in 
their environment while receiving bupropion (Becker and Dufresne , 1982) . 
Since withdrawal and emotional blunting are both prominent negative 
symptoms of schizophrenia, interest as to whether bupropion could effect 
these symptoms in schizophrenics was generated. 
Other aspects of this study include assessment of adverse reactions 
to the treatment and particularly the interactive effects of bupropion 
and the antipsychotic thiothixene. Thiothixene (Navane) was chosen as 
the antipsychotic for this study due to previous evidence that it has 
some mood elevati ng properties when used in this patie nt population 
( Becker, 1983) . It appears to be a n adequate choice for treating this 
population; therefore, by the design of this study we a re not 
withholding a proven treatment. The major objective of t his s tudy was 
to assess whether the bupropion-thiothixene combination is a better 
treatment than thiothixene alone. As bupropion will undoubtedly be used 
in combination with antipsychotics in the treatment of these patients 
upon its ma rketing in much the same manner as TCA's and MAOI's have been 
used, it is as valuable to learn if bupropion is not useful for the 
treatment of depression secondary to schizophrenia as it is to find that 
it is useful in this application. 
Methodology and Procedures 
This was a 70 day study in which thirty-eight hospitalized, 
depressed schizophrenic patients who received thiothixene in treatment 
of their psychotic symptoms additionally received either bupropion 
5. 
(n=l9) or placebo (n=l9) in a double blind trial of efficacy and safety. 
During an initial stabilization period of at least one week the dose of 
thiothixene was adjusted to optimize antipsychotic response. Patients 
remained on the same dose of thiothixene for at least on week prior to 
being started on bupropion or identical placebo; this dose of 
thiothixene was fixed for the duration of the study. After two weeks of 
thiothixene treatment patients were required to meet a minimum score of 
eighteen on the Hamilton Depression Scale. Patients were then randomly 
assigned to receive a flexible dosing regimen of either bupropion 
150-750 mg/day or placebo for up to ten weeks in a double blind fashion. 
The blind could not be broken according to Food and Drug Administration 
regulations until study completion; the only exception was in the case 
of a medical emergency. 
Inclusion and Exclusion Criteria: 
Patients were required to meet several strict inclusion and 
exclusion criteria in order to be included in the study . Each patient 
at baseline was required to meet DSM-III Diagnostic Criteria for either 
schizophrenia with superimposed atypical affective disorder or 
schizoaffective illness (A.P.A., 1980). The symptoms of the affective 
componet of their illness had to be persistent for at least two weeks 
prior to initial screening. These depressive symptoms had to remain 
prevalent during the the initial period in which they where stabilized 
on thiothixene. A minimum score of eighteen on the Hamilton Depression 
Scale had to be assessed at initial screening, weekly through 
thiothixene stabilization, and at baseline. Treatment with TCA's or 
MAOI's was not allowed for a minimum of two weeks prior to baseline. 
6. 
Patients were excluded from the study if they suffered from an organic 
mental disorder, were incapable of conversation, had history or evidence 
of a seizure disorder, had a history of alcoholism in past two years, 
had a myocaridal infarction within the last two months, were pregnant or 
lactating, or had a history of intolerance to phenothiazine or 
thioxanthine antipsychotics. 
Measures 
Patients were assessed for therapeutic efficacy using the Brief 
Psychiatric Rating Scale (BPRS), Hamilton Depression Scale, and Clinical 
Global Impression Scale (Overall and Gorham, 1962; Hamilton, 1960, Guy , 
1976). Extrapyramidal symptoms were assessed using the Dimascio 
Extrapyramidal Symptom rating scale and symptoms indicative of tardive 
dyskinesia were assessed using the Abnormal Involuntary Movement Scale 
(Guy , 1976) . The negative symptoms of schizophrenia were assessed using 
the Brief Negative Symptom Scale (Dufresne et al ., in preparation) and 
selected BPRS items. A variation of the Treatment Emergent Symptom 
Scale (Guy, 1976) was also included in the test battery to monitor for 
any adverse reactions to study medications. Each clinician assessed the 
same patient from study entry through termination. 
Clinical laboratory tests were obtained on study subjects prior to 
baseline and at study termination. These included hematology, clinical 
chemistry, and urinalysis. Patients also received a thorough physical 
exam, electrocardiogram, and electroencephalogram prior to and at the 
termination of the study. Vital signs were taken on each rating day to 
assess for side effects such as orthostatic hypotension, hypertension, 
or tachycardia. These vital signs assessment included blood pressure 
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supine and standing, heart rate supine and standing, weight, tempera-
ture, and respiratory rate. Additional tests were ordered as necessary 
for proper clinical care of the study patients. Neurological side 
effects were assessed using the Abnormal Involuntary Movement Scale and 
the Dimascio Extrapyramidal Symptom rating scale at baseline, day 7, 14, 
21, 28, 42,and 70 (Guy, 1976) . 
Analysis 
Safety assessments were made at day 0, 7, 14, 21, 28, 42, 56, and 
70 of study treatment . Safety assessments included an evaluation of 
vital signs, electrocardiogram, electroencephalogram, SMA-12, CBC with 
differential, and urinalysis as well as a complete physical exam . These 
tests were performed previous to and following the bupropion versus 
placebo phase . The assessments of therapeutic efficacy were analyzed 
using analysis of variance with repeated measures over time (Winer, 
1971). Followup tests of simple effects or simple main effects were 
performed in cases of significant overall ANOVA's with the Tukey A 
procedure being employed to test for individual cell differences . 
Statistical evaluation of side effect assessments was made using the 
appropriate nonparametric techniques such as Wilcoxon sign test and 
Chi-square test of independence (Marascuilo and McSweeney, 1977, Downie 
and Starry, 1977). 
This protocol has been approved by the Rhode Island Medical Center 
Institutional Review Board and the University of Rhode Island 
Institutional Review Board . Written informed consent was obtained from 
all subjects in accordance with federal regulations. A pregancy 




The bupropion and thiothixene combination was no more efficacious 
than the placebo and thiothixene combination. On many measures the 
control group was actually less symptomatic than the bupropion and 
thiothixene treatment group. 
Analysis of variance with repeated measures was performed on all 
assessments for study periods ending at treatment day 28 and at day 70. 
All but one patient in each treatment group finished 28 days of study 
drug treatment; this was the minimal period of time a patient could 
remain in treatment and still be considered a completed study patient. 
Of the twenty-five patients who completed all ten weeks of the study, 
nine were being treated with bupropion and thiothixene while sixteen 
were those patients treated with placebo and thiothixene. 
One of the difficulties in statistically analyzing results of 
clinical trials is that a patient is as likely to drop out of a study 
due to adverse reactions or lack of improvement while on a medication as 
they are if they respond so dramatically to treatment that they are 
discharged from the hospital. Although each group had only one dropout 
each at day 28, the patient dropout rate at day 70 was significantly 
higher in the bupropion and thiothixene group than in the placebo and 
thiothixene group (Chi-square= 5.729, df = 1, p < .02). Nine of the 
original nineteen patients completed ten weeks in the bupropion and 
thiothixene group while sixteen of the nineteen thiothixene and placebo 
treated patients completed ten weeks. Of the bupropion group, the ten 
subjects who did not complete 70 days of treatment were significantly 
more symptomatic on the BPRS at termination (Student's t = 2.29, p < 
9 . 
• 05, df = 34) than the nine subjects who did complete the full 70 days. 
Patients who did not complete the full 70 days of bupropion therapy had 
a mean score of 52.4 (S.D. = 17.15) on the BPRS at termination and those 
who did complete treatraent had a mean score of 33.3 (S.D. = 18.89). 
This would indicate that the patients who dropped prematurely from the 
bupropion group were more symptomatic than those who remained in 
treatment for the full 70 days, and that the significantly higher 
dropout rate was the result of deterioration rather than improvement. 
Analysis of change from baseline to termination of the bupropion and 
thiothixene group shows a mean improvement in those completing ten weeks 
of 6.44 (S.D. = 15.39), while those failing to complete ten weeks 
demonstrated a mean worsening of 3.30 points (S.D. = 16.19) on the BPRS. 
Statistical comparison of change from baseline on BPRS of the bupropion 
group patients fails to show a significant difference on Student's 
t-test (t = 1.34, N.S.). Thus, those patients who dropped out were more 
severely ill than those who did ·not, but deterioration during the study 
may not have been the main reason for this difference in psychiatric 
state. 
Dose-Response Relationships 
Neither dose of thiothioxene (r 2 = .03) or dose of bupropion 
(r 2 = .02) was significantly correlated with syptomatic change as 
measured by the Brief Psychiatric Rating Scale. The marked difference 
in dose of neuroleptic or antidepressant required to achieve therapeutic 
response in individual patients is well known, and neither dose of 
antipsychotic nor serum levels have ever shown a predictable dose 
response curve (Tang , 1985). Overall mean bupropion dose was 445.83 
10. 
mg. per day (S.D. = 413.16) while that of the thiothixene was 21.58 mg. 
(S.D. = 16.23) per day. 
Brief Psychiatric Rating Scale 
In terms of psychotic features as measured on the Brief Psychiatric 
Rating Scale, bupropion and thiothixene treated patients (N= 18) and 
placebo and thiothixene treated patients (N=l8) both demonstrated 
improvement over time (F = 5.68, df = 4, 136, p < .0005) with the 
control group again showing greater improvement (F= 2.57, df = 4,136, 
p < .05) over 28 days. Analysis of variance for patients completing ten 
weeks of treatment showed an overall improvement from baseline for both 
groups (F = 9.34, df = 6, 138, p < . 0001) at each week post baseline 
(Tukey A followup test, p<. 01 ). However , the thiothixene and placebo 
group (N=l8) became significantly less symptomatic than the thiothixene 
and bupropion group (N=l8) on study days 14, 21 , and 28 for those 
patients completing four weeks on study drug (See tables I and II). 
Five principal factors have been identified by principal factor 
analysis for the Brief Psychiatric Rating Scale (Guy, 1975). The 
content of these separate factors have been identified as representing 
the symptom complexes of anergia, anxiety and depression, thought 
disorder, hostility and suspiciousness, and activation. There were no 
significant changes between groups or over time on the hostility and 
suspiciousness or activation factors. Both groups showed significant (F 
= 2.73, p <.OS, df = 4,136) improvement over time in terms of a 
decrease in thought disorder. While both groups demonstrated a 
decreased score on the anxiety-depression factor over time (F 12.16, 
p < .0001, df = 4,136), the placebo and thiothixene control group 
11. 
demonstrated significant improvement from baseline at all treatment 
ratings (Tukey A test, p( . 01), whereas the bupropion group showed only 
a transient improvement from baseline at week three (Tukey A test, 
p < . 05) . On the anergia factor, the thiothixene and placebo group 
demonstrated a significant decrease from baseline at weeks one (p (.05) 
through four (p < .01) as tested using the Tukey A procedure (Winer , 
1971). (See tables III through VI) 
For the thought disorder factor on the Brief Psychiatric Rating 
Scale, there was a significant trend for improvement over time (F = 
2 . 73, df = 4,136, p( . 05) without a significant groups over time effect 
being present (See table VII). Si gnificant improvement from baseline 
occurred at weeks one and two (p ( .01) as well as week four (p < .05) . 
Both groups revealed a lack of s ignificant changes on the hostility-
suspiciousness and the activation factors of the Brief Psychiatric 
Rating Scale upon analysis of variance. 
Clinical Global Impressions 
Overall psychiatric state as measured by the Clinical Global 
Impressions Scale improved significantly over time for patients 
completing four weeks (F 12.93, df = 4,136 , p <. 0001) and for those 
completing all ten weeks (F = 14 . 27, df = 6,138, p <. 0001). All mean 
weekly ratings showed significant improvement from baseline (Tukey A 
followup test, p (.001 ). There were no between group differences as 
measured with this assessment instrument (See tables VIII and IX) . 
12. 
Negative Symptoms and Depression 
There were no differences in response to medication in terms of 
negative symptoms (tables X and XI). Both groups improved over time on 
these symptoms at four weeks (F=4.88, p< .001, df 4,136) and at ten 
weeks (F=5.53, p< .0001, df = 6,138) . The greatest improvement occurred 
at three weeks from baseline (F = 17.89, p( .001, df = 1,136), though 
both groups maintained improvement from baseline (P<.05) for the course 
of the study . 
Depressive symptomotology as measured on the Hamilton Depression 
Scale was similarly effected by both treatments over four weeks . Both 
treatment and control groups got better over time (F = 15 . 87, p < . 0001, 
df = 4,136 ) as compared to baseline (table XII) though there was no 
difference in efficacy between groups . All post baseline ratings were 
statistically significant from the baseline ratings though not diff erent 
from each other . Patients remaining in the study for ten weeks (See 
table XIII) also improved significantly over time (F = 17 . 46, df = 6, 
138, p < .0001), though there were no between group differences. 
Analysis of variance for all ten weeks using the last score forward 
method of handling of dropouts found that while both groups improved 
over time (F = 13 . 29, df = 6, 216 , p < . 0001), the placebo and 
thiothixene control group improved to a greater degree than the 
bupropion and thiothixene treatment group (F= 4 . 51, df = 6,216, 
p < .0001). 
Safety 
Experience with bupropion when used concomitantly with 
antipsychotic medication is rare; therefore this study is key to 
13. 
investigating any possible interactive effects of using bupropion in 
combination with thiothixene . Previous clinical trials have prohibited 
the use of concomitant psychotropic medications with bupropion . 
Analysis of clinical chemistry, hematology , and urinalysis data 
demonstrated no statistically or clinically significant differences 
between the control or treatment groups using repeated measures t-test 
(See table XIV) . Analysis of the data using the Wilcoxon sign test 
found no differences between groups on physical exam, electroencephalo-
gram, and electrocardiogram . Two patients with abnormal electro-
cardiograms who still qualified to enter the s tudy both suffered from 
left anterior hemi-block conducta nce disorders; these pa tients had no 
difficulty tolerating treatment and showed no e vidence of any new 
abnormalities. Three patients with mild diabetes mellitus and one with 
mild hypertension were managed wi t hout incident on t he study and 
demonstrated no signs of worsening of their condition. One young male 
patient developed a petechia during the course of treatment with 
bupropion and thiothixene that subsided quickly after the withdrawal of 
bupropion . One middle aged female patient exhibited a mild transient 
case of hypertension and tachycardia after one month on bupropion and 
thiothixene that was likely linked to worsening in her psychiatric 
condition . There were no clinically significant alterations observed on 
electroencephalogram at the termination of study medication for any 
patient . 
Data obtained on the Treatment Emergent Symptom Scale (Guy, 1976) 
was analyzed using the chi-square test of independence to determine if a 
difference in incidence of adverse effects was observed between groups . 
The data was analyzed with consideration of the frequency of reported 
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symptom per patient interview and examination for 28 days and for 70 
days of study treatment (See table XV). 
The bupropion and thiothixene treated patients reported more than 
twice the incidence of dry mouth (Chi-square of 5.81 and 4.69, df = 1, 
p < .05) and constipation (Chi-square of 4.67 and 9.6, df = 1, p < .05) 
than the placebo and thiothixene group at fo ur and ten weeks. However a 
greater percentage of placebo and thiothixene treated patients reported 
an increase in appetite (Chi-squares of 3.10 and 6.95, p < .10 and 
p < .01 respectively), menstrual disturbance (Chi-square of 4.40, df =l, 
p < .05), and decreased sex drive (Chi-square of 2 . 85, p < .10) over 
both four and ten weeks. 
Examination for neurological adverse reactions using the Abnormal 
Involuntary Movement Scale and Dimascio procedures (tables XVI, XVII, 
XVIII , XIX) yielded expected results. Little change occured in the 
symptoms of tardive dyskinesia over four weeks in both the treatment 
(n=l8) and the control (n=l8) groups and in those completing ten weeks 
of study treatment on bupropion and thiothixene (N=9) and placebo and 
thiothixene (N=l6). 
Acute extrapyramidal system disorders as measured on the DiMascio 
extrapyramidal symptom scale revealed that both groups demonstrated less 
extrapyramidal system movements over time for four weeks (F = 6.33, df 
4, 136, p< .0001) and for ten weeks (F = 3.71, df = 6, 138, p < .01). 
This is to be expected after an extended period of neuroleptic 
treatment. Tolerance to pseudoparkinson like extrapyramidal system 




The lack of response to bupropion and thiothixene in comparison to 
placebo and thiothixene is consistent with the results of similar 
studies employing a tricyclic antidepressant and neuroleptic versus a 
placebo and neuroleptic. That is, the addition of an antidepressant to 
the therapeutic regimen offered no clear advantage (Becker, 1970 and 
1976; Siris, 1978) . In a trial comparing chlorpromazine and imipramine 
to the mood elevating antipsychotic thiothixene and placebo , Becker 
demonstrated that the treatment regimens gave similar good response on 
Hamilton Depression Scale, Brief Psychiatric Rating Scale, and the Katz 
Adjustment scale while the chlorpromazine and imipramine group 
experienced more sedative and cardiovascular side effects (Becker, 
1976). In a study of 64 depressed schizophrenics this same investigator 
found a combination of amitriptyline and perphenazine to be no more 
efficacious than perphenazine and placebo with the suggestion that the 
amitriptyline may have interfered with the antipsychotic effect of the 
perphanazine (Becker, 1970). Brockington and collaborators demonsrated 
no positive effects of adding amitriptyline to a regimen of 
chlorprmazine in schizoaffective patients (Brockington et al.,1978), 
while Prusoff found a group of depressed schizophrenics showed 
improvement in depressive symptomotology with perphenazine and 
amitriptyline when compared to amitriptyline alone (Prussoff et al., 
1978). However, three-quarters of those receiving combined therapy in 
Prussoff 's study experienced an increase in blood pressure and in 
weight. In a review of the literature concerning the treatment of 
depressed schizophrenics Siris found that there were conflicting 
reports; some investigators reported an increase in positive 
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schizophrenic symptoms and some alleviation of depression with addition 
of tricyclic antidepressants or monoamine oxidase inhibitors while 
others reported no significant differences in efficacy (Siris, 1978). 
This study with the novel antidepressant bupropion shows a lack of 
benefit of the combination of bupropion and thiothixene to the mood 
elevating antipsychotic thiothixene alone. 
In examining the result of a clinical pharmacology study, there a re 
at least two key underlying issues t o consider. First, in what way does 
all the knowledge that has been obtained in terms of a drugs pharmacol-
ogical effects express itself in the data? What is consistent with 
previous studies with the agent and what is not? Secondly, in what way 
does what we know about the und erlying mecha nism and etiology of the 
disease inte r act with what we know a bout the drugs pharmacologic 
effects? In understanding t hese r e lationships we can better understand 
the implications of the findin gs and wh e re the y fit it i n t e rms of 
clincal treatment for the di sease a nd f uture r esea rch. 
In terms of both the disease state of depression in schizophrenia 
and that of the mechanism of action of bupropion - or for that matter of 
any antidepressant - there are as many questions as answers . Past 
research into the clinical treatment of depression has been largely 
empirical, with deductions as to how an antidepressant is effecting the 
disease being inferred by what the treatment had in common with other 
effective treatments . Curious but also not suprising is the manner in 
which medicinal chemists have synthesized compounds structurally similar 
to prior compounds, with pharmacologists selecting the compounds for 
potential clincial trials based on their pharmacological similarity to 
agents previously found effective . This circular phenomenon has resulted 
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in many pharmacologically similar compounds that off er few new benefits 
to the treatment of ps ychosis or depres sjon . The cycle is broken when a 
compound that does not possess a property previously thought integral to 
it being efficacious is nevertheless found to be clinically effective. 
For example, since effective antidepressants all had in common the 
abilty to increase synaptjc NE or DA as did the MAOI's, the end effect 
of increasing the synaptic catecholamine levels was considered crucial 
to their mechanism of action for many years. This theory is still 
commonly cited as the mechanism of action in many pharmacology text 
books despite the fact that this effect is immediate while clincial 
response to antidepressants does not occur for at least two to three 
weeks. 
Fortunately, the use of behavioral models of depression in animals 
has led to the development of novel antidepressant compounds that do not 
inhibit the reuptake or breakdown of serotonin or of norepinephrine 
(Shopsin et al., 1981). One such compound is bupropion. The question 
once more has become not if a compound works in depression but why does 
it work? 
A review of the literature examining the results of clincal trials 
with bupropion in the treatment of major depressive syndrome reveal that 
the compound is significantly more effective than placebo (Zung, 1983) 
and is as effective as the positive control antidepressant amitriptyline 
(Chouinard, 1983). The medication has been found useful in all but a 
few clinical trjals and has a side effect profile that rivals that of 
placebo with the exception of its abiljty to cause seizures in 
susceptible patients to the same degree as imjpramine (Dufresne et al., 
1984) . 
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The existence of useful antidepressants such as bupropion that do 
not significantly block catecholamine reuptake has led to the formation 
of more inclusive theories as to the mechanism of action of 
antidepressants. The most recent theory that takes into account both 
the temporal relationship of neurochemical event and remission of 
depressive syptoms as well as the remarkable effectiveness of the so 
called "second generation" antidepressants is that of post synaptic beta 
receptor down regulation. Clinically effective compounds such as 
bupropion all seem to cause beta receptor subsensitivity at the same 
time that remission from depressive symptoms is found to occur (Gandolf 
et al, 1983; Sellinger-Barnette 1980) though this effect is disputed 
for bupropion (Ferris and Beaman, 1983). The two to three week period 
in which increased synaptic levels of norepinephrine a re found with the 
TCA's or MAOI 's readily explains their abilty to cause post synaptic 
beta receptor down regulation. In what manner could a drug such as 
bupropion, a drug pharmacologically disimilar to established 
antidepressants , create its therapeutic effect? 
Bupropion does not inhibit type A or Type B monoamine oxidase, nor 
is it a potent blocker of NE or 5-HT reuptake (Ferris, R. M. et al., 
1983; Dufresne et al., 1984). However, bupropion given before 
intracisternal injection of 6-hydroxydopamine prevented destruction of 
dopamine containing neurons via a dose related selective antagonism 
(Cooper et al., 1980). While studies conflict as to whether bupropion 
effects serum prolactin levels (Stern et al., 1979; Laakman, G., 1982), 
the electroencephalogram arousal effect of bupropion in rats is 
selectively blocked by the effective DA antagonist pimozide (Miller and 
Wheatley, 1978). Bupropion has a 100 fold less potent effect in 
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blocking dopamine reuptake into nerve endings of rat striatum than 
nomefensine. The speculation as to bupropions mechanism of action has 
therefore been focused on its small in vitro but apparently significant 
in vivo effect on dopaminergic transmission. 
Recent findings indicate that bupropions mechanism of action is 
indeed dopaminergic in some manner. One clinical trial demonstrated an 
increase in serum homovanillic acid in depressed patients responding to 
bupropion (Golden et al., 1984), while another investigator has shown 
that bupropion may exert a DA facilitating effect by causing an increase 
in receptor affinty for DA, perhaps in the manner that benzodiazepines 
facilitate the binding of GABA to its receptor (Blitzer, 1985, personal 
communication) . A previous clinical trial reported an alteration in 
perception with bupropion in some depressed patients in a manner similar 
to that seen with dopaminergic agonistic drugs such as L- DOPA or 
amantidine (Becker & Dufresne, 1982). The fact that many of these 
patients had been treated prior to the two week washout period at some 
time with dopamine antagonistic neuroleptic leads to an interesting 
speculation; could bupropion's small DA agonistic effect be amplified in 
these patients due to supersensitive DA receptors? Only two of those · 
patients showing the altered perceptions showed any evidence of a 
coexiting psychotic component to their illness. Furthermore, a 
significant number of patients treated in this study showed signs of DA 
stimulation such as hand tremor and agitation (Dufresne et al., 1985). 
Nornefensine, an antidepressant that increases DA release as well as 
inhibiting NE reuptake in synapses resembles bupropion in that it is 
self-administered in rats and primates (Dufresne et al., 1984), has few 
anticholinergic and cardiovascular side effects, and has an energizing 
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stimulant effect in some patients (Shopsin et al., 1981). When compared 
wi th ami tr yptyline in a lar ge double-blind trial bupropion trea t ed 
patients reported more agitation and excitement, nauseau and vomiting , 
and decreased appetite than the positive control (Chouinard, 1983). All 
these effects could be related to a dopamine agonistic mechanism. An 
increase in dopaminergic transmission could account for post synaptic 
beta receptor down regulation. 
Stepwise multiple regression was performed using the individual 
items of the Negative Symptom Scale as predictors with change from 
baseline on the Brief Psychiatric Rating Scale for both groups at day 28 
(N = 18 for both groups) being the dependent variable. The single best 
predictor of nonresponse to treatment was the presence of emotional 
blunting. The presence of emotional blunting has been linked to 
enlargement of cerebral ventricles in schizophrenic patients (Andreasen, 
1982) . In this study, the presence of emotional blunting was an 
indicator of poor response to thiothixene treatment. Emotional blunting 
was negatively correlated (r = -.51) with improvement from baseline at 
-four weeks and was the best predictor of thiothixene treatment 
nonresponse with a multiple R' of .2608 being observed (F=5.65, df 
1,18 ,p < .05) . No significant relationship between treatment 
nonresponse and emotional blunting was found in the bupropion and 
thiothixene treatment group patients. This finding is one more atypical 
difference in treatment response patterns between these groups that 
leads to speculation that bupropion interfered with thiothixene's 
mechanism of action in aleviating the anxiety and depression symptoms in 
these patients. Bupropions possible dopamine agonism worsened these 
symptoms in our sample of depres sed schizophrenics whereas the drug 
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typically causes improvement in patients with major depressive syndrome. 
The higher dropout rate of the placebo and thiothixene group at 
days 42 and 70 could lead one to suspect that improvement may have 
occured to a greater degree in this group partly due to their being able 
to tolerate a longer period of treatment with thiothixene than the 
bupropion and thiothixene group . This finding also suggests a dopamine 
agonistic effect of bupropion which interfered with the therapeutic 
effect of dopaminergic receptor blockade of the thiothixene in a 
subgroup of schizophrenics with a secondary depression . Primarily 
depressed patients should not, theoretically, be so effected. In fact, 
bupropion would reduce and not increase anxiety and depression in a 
patient suffering from a primarily depressive disorder . 
The results of the current study supports the possibility that 
bupropion antagonized the therapeutic effect of thiothixene on some 
parameters. This would suggest that the effect of the mood elevating 
antipychotics in treating depressed shizophrenia is related to the 
unique effects that these drugs have in treating this syndrome . That 
is, bupropion causes an increase in dopaminergic transmission and 
subsequent beta receptor down regulation that may cause improvement in 
previously treatment resistant major depressive syndrome patients . 
Increasing the release of DA into the synapse or the binding affinity of 
DA to the receptor, as the case might be, would antagonize the 
therapeutic effect that the thiothixene is having on the symptoms of a 
syndrome that combines the symptomotology of major depressive syndrome 
and the schizophrenias but is characteristically neither in its 
neuropathology or in its response to pharmacologic intervention . 
Treating the depressive component of the disease as a separate entity 
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from the positive symptomotology of schizophrenia does not appear 
rational, as antidepressants do not impove the depressive symptoms and 
can exacerbate psychosis in many cases. Rather, viewing the syndrome as 
a disease which is distinct from major depressive syndrome and the 
schizophrenias, but which exhibits symptomatic components of each, 
offers a better structure in which to explore underlying pathology and 
possible treatments for this syndrome . Lack of any differences due to 
bupropion on the Abnormal Involuntary Movement Scale may suggest that 
bupropion ' s dopaminergic facilitating activity may be limited to 
mesolimbic but not striatonigral dopaminergic systems . 
Since the addition of antidepressants to antipsychotics in these 
patients usually is ineffective, we may assume that this syndrome is 
more similar to the schizophrenias in etiology and pathology than the 
depressive spectrum disorders . A possible explanation for the effect 
that TCA's are found to ha ve in a f ew studies may be related to the 
relief of antipsychotic induced akinetic symptoms due to the powerful 
anticholinergic effects of amitriptyline and pharmacologically similar 
antidepressants than relief of true depressive symptoms . Previous 
studies have shown the relief of akinetic syptoms in schizophrenics with 
pseudo-parkinsonism using anticholinergic medication that in some cases 
resembles the relief of many depressive symptoms (Van Putten and May , 
1978) . The results of a factor analytic study also suggests that the 
depressive symptoms of this syndrome is characteristically distinct from 
that of major depressive syndrome or schizophrenia (Becker , 1985) . 
Avenues for future research should focus on controlled double-blind 
trials of single agents rather than combination therapies and further 
work to characterize this syndrome as a separate psychiatric disease 
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Two groups of depressed schizophrenic patients were treated with 
either bupropion and thiothixene or placebo and thiothixene and assessed 
for efficacy and safety. On the Brief Psychiatric Rating Scale total 
scores , both groups improved over time at four and at ten weeks . 
However, the placebo and thiothixene group did better than the bupropion 
and thiothixene group over four weeks (F=2.57 , p < . 05) , though not 
significantly so over ten weeks . On the Brief Psychiatric Rating Scale 
component scores for anxiety and depression , the placebo and thiothixene 
group improved over time to a greater degree than bupropion and 
thiothixene group . For the anergia component score, the placebo and 
thiothixene group improved significantly over time while the bupropion 
and thiothixene group did not . In re gard to t hought di s order, both 
groups improved over time to a similar degree . Neither group improved 
over time on the acti vation or the hostility and suspiciousness 
component scores. 
On the Clinical Global Impression of severity of illness, both 
groups improved over time at four and ten weeks , but neither group did 
significantly better than the other. In regard to depressive 
symptomatology as measured on the Hamilton Depression Scale, both groups 
improved significantly over time with no between group differences for 
those patients completing both four and ten weeks . On the Negative 
Symptom Scale, both groups improved over time to a similar degree at 
both four and ten weeks . 
A significantly greater number of patients (N=9) dropped out after 
four weeks of treatment in the bupropion and thiothixene group, while 
only two patients in the bupropion and thiothixene dropped out between 
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four and ten weeks of treatment with study medications. This unequal 
rate of premature study termination appeared to be the result of a 
worsening in psychiatric condition. 
The use of bupropion in addition to thiothixene in the treatment of 
depressed schizophrenics appears to be unjustified and possibly 
contraindicated. The results and conclusions of this study is similar 
to most well controlled clinical trials in which an antidepressant 
medication is given in combination with an antipsychotic. This 
pharmacotherapeutic strategy is not recommended. 
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Mean S . D. 
44 . 4 11.6 
38 . 1 16 . 3 
40 . 8 14 . 9 
41.0 19 . 7 





Mean S . D. 
45 . 3 9 . 0 
36.4 11.8 
35 . 8 10 . 5 
35 . 3 11.4 
31. 9 10 . 9 
Table I. Average scores for patients r ema i ning for four weeks on 
drug for the Brief Psychiatric Rating Scale . Totals above thirty 
on this scale represents a woderate l evel of psychotic symptoms , 
above forty-five represents pronounced psychotic symptomotology, 
and a total greater than sixty represents very severe 
psychopa thology . Placebo and thiothixene group improved 
significantly over time while t he bupropion only group did not . 
The placebo and thiothixene group demonstrated l ess 
symptomotology (p < . 05) than the bupropion ond thiothixene gr oup 
at day 14 , 21, and 28 . 
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Brief Psychiatric Rating Scale 
Ten Weeks 
Bupropion & Placebo & 
Thiothixene Thiothixene 
N = 9 N = 16 
Treatment 
Period MEAN S.D. MEAN S.D. 
BASELINE 39 .7 8.9 46.6 8.8 
DAY 7 34.4 13.7 37 .4 11.9 
DAY 14 34.7 12.4 36.0 11.1 
DAY 21 29 .7 10.5 35 .4 12.1 
DAY 28 32 .6 ll.6 32 .1 11.4 
DAY 42 30.9 11.3 33 .4 11.8 
DAY 70 33.2 16.4 29.5 8.8 
TABLE II . Brief Psychiatric Rating Scale tota l scores for those 
patients completing ten weeks of study trea tment. Bot h groups 
i mproved f r om base line (p < . 001) while there was a trend for the 
placebo and thiothixene group to have jmproved to a greater 
degree (p < . 10) over time • Significantly more patients 
dropped out of the bupropion and thiothixene group than the 
placebo and thiothixene group . 
Anergia Factor Score 
Bupropion & Placebo & 
Thiothixene Thiothixene 
N = 18 N = 18 
Treatment 
Period MEAN S.D. MEAN S.D. 
BASELINE 12.5 4.1 12.9 3.8 
DAY 7 10.3 5.3 10.1 4.6 
DAY 14 10.8 4.6 9.2 4.7 
DAY 21 10.4 5.9 8.6 4.9 
DP.Y 28 11.4 5.4 7.9 4.3 
TABLE IIJ. Anergia factor score for the Brief Psychiatric scale . 
The patients in the thiothixene and placebo ~roup improved 
s ignificantly (p < .05) from baseline while the buproi:ion group 
die not. 
34. 
Anxie ty and Depression Factor 
Treatment Bupropion & Placebo & 
Period Thiothixene Thiothixene 
N = 18 N = 18 
MEAN S.D. MEAN S.D. 
BASELINE 12.4 3.2 13.6 2.9 
DAY 7 10.6 5.0 9.9 3.9 
DAY 14 11.3 5.5 9.7 3.4 
DAY 21 9.8 5.1 9.1 3.5 
DAY 28 10.8 5.0 8.0 3.7 
TABLE IV. Bupropion and thiothixene group improved from 
baseline at week 3 only (p < .05) while placebo and thiothixene 
group showed significant improvement on anxiety and depression 
Brief Psychiatric Rating Scale factor score from baseline at week 
one and thereafter (p < .01 ). 
35 . 
BPRS Hostility and 
Suspiciousness Factor Score 
Bupropion & Placebo & 
Treatment Thiothixene Thiothixene 
Period N = 18 N = 18 
Mean S.D. Mean S.D. 
BASELINE 5.2 2.5 5.2 2.3 
DAY 7 4.9 2.8 5.1 2.6 
DAY 14 5.4 3.2 4.7 2.0 
DAY 21 6.3 4.8 4.8 2.9 
DAY 28 6.8 4.3 4.7 2.4 
TABLE V. Hostility and suspiciousness factor score for the 
Brief Psychiatric Rating Scale for patients completing four 
weeks. There were no significant differences between groups or 
over time. 
36. 
Activation Factor Score 
Treatment Bupropion & Place bo & 
Period Thiothixene Thiothixene 
N = 18 N= 18 
MEAN S . D. MEAN S . D. 
BASEL IKE 5 . 8 3 . 3 5 . 9 2 .7 
DAY 7 5 . 3 2 . 8 5 . 2 2 .4 
DAY 14 5 .7 2 . 9 5 . 6 2 . 5 
DAY 21 5 . 9 3 . 4 6 . 1 3 . 0 
DAY 28 5 . 4 3. 3 5 . 3 2 . 2 
TABLE VI . Br i ef Psychiatrjc Rating Scale activation factor 
score . There were no significant differences between groups or 
over time . 
37 . 
Thought Disorder Factor Score 
Bupropion & Placebo & 
Treatment Thiothixene Thiothixene 
Period N = 18 N = 18 
Mean S.D. Mean S.D. 
BASELINE 8 .3 3 .8 8 .0 3.3 
DAY 7 7.2 3.4 6. 4 2. 6 
DAY 14 7.3 3 .3 6 .3 2 . 5 
DAY 21 7.5 3.7 7.2 2. 9 
DAY 28 7 . 9 3.8 6 . 2 2 . 3 
TABLE VII . The thought disorder factor score of the Brief 
Psychiatric Rating Sc~le for patients complet i ng four weeks. 
There were no between group differ ences . Both groups demontrsted 
a decrease i11 thought disorder as compared from base line that was 
statistically signifjcan t ( p< . 05) at dnys seven, fourteen, and 
twenty-eight . 
38 . 
Clinical Global Impressions 
Bupropion & Place bo & 
Treatment Thiothixene Thiothixene 
Period N = 18 N 18 
Mean S.D. Mean S.D. 
BASELINE 4.7 1.0 4.7 .67 
DAY 7 4 .1 1.6 4 .1 .96 
DAY 14 4.2 1.3 4.0 1.0 
DAY 21 3.9 1.5 3.6 1.1 
DAY 28 3 .9 1.5 3.6 1.1 
TABLE VIII. Clinical Global Impressions Severity of illness 
rating for patients completing four weeks of treatment . A rating 
of 1ine represents absence of ps ychopathology. Ratings of three 
represents mild psychiatric illness, of four moderate illness , 
and of six severe psychiatric dysfunction. A rating of seven 
is reservel for the most extremely ill patient. Both groups 
show improvement (F=l2.93, df = 4,136 ,P < .0001) over time . 











Clinical Global Impressions 
Bupropion & Placebo & 
Thiothixene Thiothixene 
N = 9 N = 16 
Mean S.D. Mean S.D. 
4.5 1. 2 4.8 .66 
3.8 1.6 4.3 . 86 
3.9 1.4 4.0 1.1 
3.4 1.3 3.6 1.2 
3 .3 l. 3 3.7 1.1 
3. Lf 1. 3 3 . 6 1.2 
3.6 1.4 3 . 2 1.0 
TABLE IX. Clinical Global Impressions severity of illness 
rating for patients completing ten weeks of treatment. Both 















Mean S . D. 
7 . 0 3 . 5 
3 . 93 3 . 82 
5 . 6 4 . 48 
3.66 4 . 15 




Mean S . D. 
6 . 75 4 . 67 
5.62 4 .86 
4 . 62 4 . 04 
4.06 4 . 42 
4 . 38 4.66 
Table X. Lack of significant changes on the Negative Symptom 
Scale for patients completing fo ur weeks of study treatment . 
Total scores of between five and ten can be interpreted as · 
moderate levels of the negative syoptoms of schi zophrenia, whi le 
above ten represents pronounce d negati ve synptomotology . 
41. 
42. 
Negative Symptom Scale 
Ten Weeks 
Bupropion & Placebo & 
Treatment Thiothixene Thiothixene 
Period N 9 N = 16 
MEAN S.D. MEAN S.D. 
BASELINE 5.6 3.0 7.4 4.7 
DAY 7 3.6 3.3 6.1 5.0 
DAY 11+ 4.4 4.2 4.4 3.8 
DAY 21 2.7 2.] 4.3 4.7 
DAY 28 3.7 2.8 4.6 4.8 
DAY 42 3.2 2 .8 4.2 4.4 
DAY 70 2.4 2.2 3 .7 4 .0 
TABLE XI . Both groups improved significantly over time 








Hamilton Depression Scale 
Four Weeks 
Bupropion & Place bo & 
Thiothixene Thiothixene 
N=l8 N=l8 
Mean S.D. Mean S.D. 
28 .9 10.3 32 .0 8 .16 
20 .1 15.4 19.4 11.1 
22 . 2 14.7 19.2 11.9 
18 .9 15.4 17.9 12.6 
22 .7 16 . 3 16 . 0 13 . 9 
TABLE XII . Hamilton depression scale means for patients 
finishing four weeks . Total ratings above eigh t een are 
considered to represent moderate depressive syoptomotology, while 
total scores greater than thirty represent severe depressive 
psychopathology. There were no significant differences between 
bupropion and th i othixene versus the placebo and th i othixene 
groups over time . Both groups ioproved significantly over time 
















MEAN S . D. 
23 .9 6 .6 
15 .7 11. 7 
15 . 4 12 . 0 
12 . 0 12 . 6 
14 . 7 12 . 4 
12 . 0 11.1 





MEAN S. D. 
31.8 8 . 6 
19 . 4 11. 6 
17 . 8 11. 9 
16 . 2 12 . 0 
14 . 8 13 . 8 
14 . 4 12. . 5 
10 . 7 11.3 
TABLE XIII . For study patients completing ten weeks, both groups 















Mean S.D. Mean S.D. 
-----------------------------------------------------------------
Hemaglobin 15.1 1.3 14.57 1.5 15.3 1.2 14.8 1.2 
Hematocrit 44.8 3.9 44.5 3.4 45.l 3.4 43.9 3.7 
RBC x 10l6 5.0 . 38 5.0 .49 5.0 .41 4.89 .44 
Platlet 
Estimate All WNL All WNL All WNL All WNL 
Total 
WBC x 10l3 8.3 2.8 7.6 2.0 7.9 2.5 7.4 2.6 
Differential 
-----------------------------------------------------------------
Neutrophils 65 . 9 7.4 63 . 0 9.6 64.3 10.5 61.56 7. 0 
(41-77% WNL) 
Lymphocytes 26.8 8.4 30.5 8.4 27.6 8.3 29.5 8.7 
(22-44% WNL) 
Monocytes 3.8 3.2 4.7 2.4 5.11 3.4 5.12 3.1 
(3-6% WNL) 
Eosinophils 2.8 2.3 1.5 1.5 2.11 2.1 3.00 2.7 
(0-2.7% WNL) 
45. 
















Specific Gravity 1.018 .007 1.021 .009 1.016 .005 1.017 .005 
(1.009-1.026 WNL) 
Acetone 0 0 0 0 
Protein 0 0 0 1 
(no. of positives) 
Glucose 0 0 0 0 
WBC 0 0 0 0 
RBC 0 1 0 0 
Table XIV. There were no significant differences between groups 





TREATMENT EMERGENT SYMPTOM SCALE 
BUPROPION & THIOTHIXENE 
BASELINE FOUR WEEKS TEN WEEKS 
ADVERSE REACTIONS 
(Percent Reporting) 
Hallucinations 15.79 6.67 8.74 
Euphoria 5.26 2.67 1.94 
Agitation 10.53 16.00 16.50 
Irresponsible Behavior 5.26 6.67 5.83 
Aggression o.oo 4.00 3.88 
Insomnia 36.84 18.67 15.53 
Tiredness 36.84 18.67 15.59 
Drowsiness 10.53 4.00 5.83 
Decreased Appetite 5.26 8.00 9.71 
Increased Appetite 5.26 0.00 0.00 
Headache 0.00 4.00 3.88 
Myoclonus 0.00 0.00 0.00 
Cramps 0.00 2.67 2.91 
Rigidity 26.32 9.33 6.80 
Tremor 31.58 18.67 17.48 
Dystonia 0.00 0.00 1. 94 
Akathesia 15.79 9.33 7. 77 
Parasthesia 0.00 0.00 ' 0.00 
Tinnitus 5. 26 0.00 0.00 
Vertigo 5. 26 2.67 1. 94 
Joint Pain 0.00 0.00 0.00 
Muscle Pain 5.26 5.33 3.88 
Menstrual Disturbance o.oo o.oo 0.00 
Blurred Vision 21.05 13.33 12.62 
Dry Mouth 21.05 28.00 27.18 
Increased Salivation 0.00 0.00 0.00 
Constipation 15.79 9.33 9.71 
Diarrhea 5.26 0.00 0.00 
Urinary Retention 0.00 0.00 0.00 
Nocturia 0.00 1.33 0.97 
Sweating 0.00 o.oo 0.00 
Nauseau/Vomiting 0.00 6.67 6.80 
Impotence 5.26 1.33 0.97 
Fainting/Dizziness 0.00 2.67 2.91 
Palpitations 0.00 0.00 0.00 
Peripheral Edema o.oo 0.00 0.00 
Cold Extremities 0.00 0.00 0.00 
Skin Lesi on/Rash 0.00 1.33 0.97 
Mem brane Lesions o.oo 0.00 0.00 
Alopecia 0.00 0.00 o.oo 
Hirsutism 0.00 0.00 0.00 
49. 
TABLE XV. (Continued) 
TREATMENT EMERGENT SYMPTOM SCALE 
BUPROPION & PLACEBO 
BASELINE FOUR WEEKS TEN WEEKS 
ADVERSE REACTIONS 
(Percent Reporting) 
Hallucinations 15.79 10.81 9.76 
Euphoria 5.26 1.35 1.63 
Agitation 10.53 9.46 6.50 
Irresponsible Behavior 5.26 5.41 3.25 
Aggression 0.00 1.35 .81 
Insomnia 36.84 24.32 23.58 
Tiredness 36.84 16.22 17.07 
Drowsiness 10.53 1.35 3.25 
Decreased Appetite 10.53 4.05 4.88 
Increased Appetite 10.53 4.05 6.50 
Headache 10.53 6.76 4.88 
Myoclonus 0.00 0.00 0.00 
Cramps 5.26 1.35 0.81 
Rigidity 21.05 12.16 12.20 
Tremor 5.26 21.62 20.33 
Dystonia 5.26 2.70 1.63 
Akathesia 21.05 12.16 9.76 
Parasthesia 0.00 1.35 0.81 
Tinnitus 0.00 0.00 0.00 
Vertigo 0.00 0.00 0.81 
Joint Pain 5.25 12.16 10.57 
Muscle Pain 5.26 16.22 13.01 
Menstrual Disturbance 0.00 6.76 4.88 
Blurred Vision 15.79 8.11 8.94 
Dry Mouth 10.53 12.16 15.45 
Increased Salivation 0.00 1.35 0.81 
Constipation 5.26 1.35 0.81 
Diarrhea 0.00 0.00 0.00 
Urinary Retention 0.00 0.00 0.81 
Nocturia 0.00 1.35 1.63 
Sweating 0.00 0.00 0.00 
Nauseau/Vomiting 5.26 5.41 4.07 
Impotence 5.26 6.76 4.88 
Fainting/Dizziness 0.00 4.05 4.88 
Palpitations 0.00 0.00 0.00 
Peripheral Edema 0.00 0.00 0.00 
Cold Extremities 0.00 0.00 0.00 
Skin Lesion/Rash 10.53 2.70 6.50 
Membrane Lesions 0.00 0.00 0.00 
Alopeci.a 0.00 0.00 0.00 
Hirsutism 0.00 1.35 0.81 
so. 
Abnormal Involuntary Movement Scale 
Bupropion & Bu pro pion 
Thiothixene & Placebo 
1~=18 N=18 
Treatment 
Period Mean S. D. Mean S.D . 
Baseline 3.0 5 . 8 1.33 2.42 
Day 7 2.1 4 . 1 1.61 2.35 
Day 14 2 . 5 5 . 8 1. 94 3.28 
Day 21 2 . 8 5 .7 2. 61 3 . 34 
Day 28 2.9 5 . 6 1.61 2 . 54 
Table XVI. No significant differences over four weeks on 


































2 .4 3 .4 
TABLE XVII. No effects were demonstrated on tardive dyskinesia 
symptoms for those patients com~leting ten weeks of study 
treatment. 
51. 
DiMascio Extrapyramidal Symptom Scale 
Bupropion & Placebo & 
Thiothixene Thiothixene 
Treatment 
Period Mean S.D. Mean S .D. 
Baseline 3 . 72 2.9 3.44 3.3 
Day 7 2.39 2.8 2 . 22 1.6 
Day 14 2.33 3 .1 1. 61 1.2 
Day 21 2.22 3 .1 2 .22 2.2 
Day 28 1.83 2.9 2.17 2.9 
Table XVIII . Improvement on EPS for both groups over trea tment 
period ( F=6 . 33, p<. 0001) . There was no sjgnificant difference 
52. 











TABLE XlX . 
53. 
Dimascio Extrapyrarnidal System 
Disorder Scale 
Ten Weeks 
Bupropion & Placebo & 
Thiothixene Thiothixene 
N=9 N=l6 
MEAN S.D. MEAN S.D. 
2 .4 2 . 1 3 .4 3 .3 
1.3 0.9 2.3 1. 7 
1.4 1.2 1.6 1.3 
1.3 1.8 2 . 2 2.1 
0 . 9 0 .7 2.4 3 .0 
0 . 9 0 .7 2. 5 2 . 5 
0 . 9 1.6 1.4 1. 7 
Both groups demonstrated a decrease in extrapyramidal 
system symptoms over time for those pa tients coopleting ten 
weeks . 
